Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
2.
Am J Transplant ; 14(10): 2417-21, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25138148

ABSTRACT

Clinical disease due to human T cell lymphotropic virus type 1 (HTLV-1), a retrovirus endemic in certain regions of the world, is rarely reported after solid organ transplantation. In 2009, universal deceased donor organ screening for HTLV-1 was discontinued in the United States. We report the first case of donor-derived HTLV-1-associated myelopathy in a kidney transplant recipient from the United States. The patient, who was HTLV-1-seronegative prior to transplantation, likely acquired HTLV-1 infection from a seropositive organ donor. In this era when screening of donors and recipients for HTLV infection is not mandatory, clinicians should be vigilant in recognizing the risk and potential occurrence of this donor-derived infection in recipients with epidemiologic exposures.


Subject(s)
HTLV-I Infections/transmission , Kidney Transplantation , Muscular Diseases/etiology , Tissue Donors , Humans , Male , Middle Aged
3.
Am J Transplant ; 9(12): 2800-7, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19845581

ABSTRACT

Membranous nephropathy (MN) recurs posttransplant in 42% of patients. We compared MN recurrence rates in a historical cohort transplanted between 1990 and 1999 and in a current cohort diagnosed by protocol biopsies, we analyzed the progression of the disease and we assessed the effects of anti-CD20 antibodies (Rituximab) on recurrent MN. The incidence of recurrent MN was similar in the historical (53%) and the current cohorts (41%), although in the later the diagnosis was made earlier (median, 4[2-21] months vs. 83[6-149], p = 0.002) and the disease was clinically milder. Twelve out of 14 patients (86%) with recurrent MN in the current cohort had progressive increases in proteinuria. Eight recipients were treated with Rituximab after their proteinuria increased from median, 211 mg/day (64-4898) at diagnosis to 4489 (898-13 855) (p = 0.038). Twelve months post-Rituximab, 75% of patients had either partial (PR) or complete remission (CR). After 24 months 6/7 (86%) had PR/CR and one patient relapsed. Posttreatment biopsies showed resorption of electron dense immune deposits in 6/7 cases and were negative for C3 (4/7) and IgG (3/7). Protocol biopsies allow early diagnosis of subclinical recurrent MN, which is often progressive. Treatment of recurrent MN with Rituximab is promising and should be evaluated in a prospective randomized controlled trial.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Glomerulonephritis, Membranous/diagnosis , Glomerulonephritis, Membranous/drug therapy , Adult , Antibodies, Monoclonal, Murine-Derived , B-Lymphocytes , Biopsy , Cohort Studies , Early Diagnosis , Female , Glomerulonephritis, Membranous/pathology , Humans , Kidney Glomerulus/ultrastructure , Kidney Transplantation/adverse effects , Lymphocyte Count , Male , Middle Aged , Recurrence , Rituximab
4.
Am J Transplant ; 8(6): 1318-22, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18444918

ABSTRACT

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. MN can recur after kidney transplantation causing proteinuria, allograft dysfunction and graft failure. In this study we assessed the incidence of MN recurrence utilizing surveillance graft biopsies. The study included 1310 renal allograft recipients from 2000 to 2006. Glomerular diseases were the cause of kidney failure in 28% of patients and 23 (2%) had idiopathic MN. Recurrent MN was diagnosed in eight of 19 patients included in this analysis (42%) 13 +/- 20 months (median = 4; range 2-61 months) after transplant. The initial clinical manifestations of recurrent MN were mild or absent. Urine protein excretion was 825 +/- 959 (64-2286) mg/day and three patients had no proteinuria. Five of seven patients who did not receive additional immunosuppression for MN had significant increases in proteinuria during follow up and three became nephrotic. At diagnosis, light microscopic changes were subtle or absent. All patients had granular glomerular basement membrane deposits of IgG but little or absent C3 by immunofluorescence. Subepithelial deposits were observed in all cases by electron microscopy. In conclusion, idiopathic MN recurred in 42% of patients after transplantation. The initial clinical and histologic manifestations are subtle but the disease is progressive.


Subject(s)
Glomerulonephritis, Membranous/pathology , Kidney Transplantation/adverse effects , Kidney/pathology , Adult , Aged , Biopsy , Female , Glomerulonephritis, Membranous/epidemiology , Glomerulonephritis, Membranous/etiology , Humans , Incidence , Male , Middle Aged , Recurrence
5.
Am J Med ; 109(8): 665-78, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11099687

ABSTRACT

Acute renal failure is commonly due to acute tubular necrosis (ATN), the latter representing an acute, usually reversible loss of renal function incurred from ischemic or nephrotoxic insults occurring singly or in combination. Such insults instigate a number of processes-hemodynamic alterations, aberrant vascular responses, sublethal and lethal cell damage, inflammatory responses, and nephron obstruction-that initiate and maintain ATN. Eventually, reparative and regenerative processes facilitate the resolution of renal injury and the recovery of renal function. Focusing mainly on ischemic ATN, this article reviews evidence indicating that the inordinate or aberrant generation of reactive oxygen species (ROS) may contribute to the initiation and maintenance of ATN. This review also discusses the possibility that ROS may instigate adaptive as well as maladaptive responses in the kidney with ATN, and raises the possibility that ROS may participate in the recovery phase of ATN.


Subject(s)
Acute Kidney Injury/metabolism , Glomerular Filtration Rate , Reactive Oxygen Species/metabolism , Acute Kidney Injury/physiopathology , Adenosine Triphosphate/metabolism , Cell Hypoxia , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...